Creative Planning Boosts Position in Editas Medicine, Inc. (NASDAQ:EDIT)
Creative Planning boosted its position in shares of Editas Medicine, Inc. (NASDAQ:EDIT) by 8,910.9% during the second quarter, according to its most recent filing with the SEC. The fund owned 9,101 shares of the company’s stock after buying an additional 9,000 shares during the period. Creative Planning’s holdings in Editas Medicine were worth $153,000 as of its most recent SEC filing.
Several other hedge funds have also recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its stake in shares of Editas Medicine by 72.2% in the first quarter. Bank of America Corp DE now owns 5,936 shares of the company’s stock worth $133,000 after buying an additional 2,489 shares during the period. Barrett Asset Management LLC acquired a new position in Editas Medicine during the first quarter worth approximately $223,000. First American Bank acquired a new position in Editas Medicine during the second quarter worth approximately $251,000. Dynamic Technology Lab Private Ltd acquired a new position in Editas Medicine during the first quarter worth approximately $269,000. Finally, Fox Run Management L.L.C. acquired a new position in Editas Medicine during the first quarter worth approximately $272,000. Institutional investors and hedge funds own 67.87% of the company’s stock.
Editas Medicine, Inc. (NASDAQ EDIT) traded up 9.53% on Friday, reaching $21.60. The company’s stock had a trading volume of 1,081,197 shares. The company’s market cap is $883.72 million. Editas Medicine, Inc. has a 52-week low of $12.43 and a 52-week high of $29.20. The firm’s 50-day moving average price is $17.07 and its 200 day moving average price is $18.99.
Editas Medicine (NASDAQ:EDIT) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by $0.01. The company had revenue of $3.10 million for the quarter, compared to the consensus estimate of $2.20 million. Editas Medicine had a negative return on equity of 69.21% and a negative net margin of 2,091.36%. The business’s revenue for the quarter was down 8.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.54) earnings per share. Equities analysts anticipate that Editas Medicine, Inc. will post ($2.84) EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2017/08/11/creative-planning-boosts-position-in-editas-medicine-inc-nasdaqedit.html.
Several equities analysts have recently issued reports on the company. Zacks Investment Research raised Editas Medicine from a “hold” rating to a “buy” rating and set a $19.00 price target on the stock in a research note on Wednesday, July 12th. SunTrust Banks, Inc. began coverage on Editas Medicine in a research note on Thursday, July 13th. They issued a “hold” rating and a $17.00 target price on the stock. J P Morgan Chase & Co set a $27.00 price target on Editas Medicine and gave the stock a “hold” rating in a report on Wednesday. Cann restated a “hold” rating on shares of Editas Medicine in a report on Thursday. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Editas Medicine in a report on Tuesday, July 18th. Five analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $25.03.
In related news, insider Gerald Frank Cox acquired 4,000 shares of the firm’s stock in a transaction on Friday, June 2nd. The stock was purchased at an average cost of $14.15 per share, with a total value of $56,600.00. Following the acquisition, the insider now owns 4,000 shares of the company’s stock, valued at approximately $56,600. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Kevin Bitterman sold 1,000,000 shares of the business’s stock in a transaction that occurred on Monday, May 22nd. The stock was sold at an average price of $17.00, for a total value of $17,000,000.00. The disclosure for this sale can be found here.
About Editas Medicine
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Want to see what other hedge funds are holding EDIT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Editas Medicine, Inc. (NASDAQ:EDIT).
Receive News & Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.